 ABBV-CLS-4-84 is a novel drug candidate that targets two key proteins involved in suppressing T-cell activity, protein tyrosine phosphatase-1b, PTP-1b, and protein tyrosine phosphatase-N2, PTP-N2. This compound was found to be highly effective at increasing T-cell activity against tumors while avoiding any significant side effects. In addition, this compound was also found to increase the effectiveness of checkpoint inhibitors such as alpha, PD-1, making it a potentially powerful tool in the fight against cancer. This article was authored by Shu Wei Liang, Eric Tran, Shindu, and others.